QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook

Key Takeaway: QIAGEN has reported its preliminary results for Q1 2026, achieving its adjusted EPS outlook. However, the sales trends were mixed, indicating variability in performance across different segments. The company has also updated its full-year outlook for 2026, reflecting these preliminary results.